10-Q: PACS Group Reports Strong Q3 Growth Amid Regulatory Scrutiny

PACS Group announced significant revenue and net income increases for Q3 2025, alongside ongoing regulatory investigations and identified material weaknesses in internal controls.

Summary

• Total revenue for the nine months ended September 30, 2025, increased by 36.4% to $3.93 billion, up from $2.88 billion in the prior year period.
• Net income for the nine months ended September 30, 2025, surged by 587.5% to $131.68 million, compared to $19.15 million in the same period of 2024.
• Operating income for the nine months ended September 30, 2025, grew by 320.6% to $214.91 million, from $51.09 million in the prior year.
• The company expanded its operations by adding seven stand-alone facilities and acquiring five properties, increasing skilled nursing beds by 495 and assisted living beds by 271.
• Overall occupancy rate for skilled nursing services decreased to 88.9% for the nine months ended September 30, 2025, from 90.8% in the prior year, primarily due to decreases in New and Ramping facilities.
• Average Medicaid daily rates increased by 7.7% due to state reimbursement increases and participation in supplemental payment programs.
• Identified material weaknesses in internal control over financial reporting related to control environment and revenue recognition processes.
• The company is subject to multiple ongoing regulatory investigations by the U.S. Department of Justice (DOJ) and the SEC, as well as securities class action and shareholder derivative lawsuits.
• Multiple forbearance agreements have been entered into with lenders regarding the Amended and Restated Credit Facility due to technical events of default, with the forbearance period extended through November 30, 2025.

Sentiment

Score: 3

Explanation: While financial performance shows strong growth in revenue and net income, the pervasive and severe legal, regulatory, and internal control issues, coupled with the ongoing credit facility forbearance, create significant uncertainty and risk. The substantial increase in legal costs and the identified material weaknesses overshadow the operational positives, indicating a challenging environment for the company.

Positives

• Total revenue increased by 36.4% to $3.93 billion for the nine months ended September 30, 2025, demonstrating strong top-line growth.
• Net income saw a substantial increase of 587.5% to $131.68 million for the nine months ended September 30, 2025, indicating improved profitability.
• Operating income grew by 320.6% to $214.91 million, reflecting enhanced operational efficiency.
• Net cash provided by operating activities increased by $104.9 million to $407.61 million for the nine months ended September 30, 2025, driven by improved operational performance and efficient accounts receivable collections.
• The company expanded its portfolio by adding seven facilities and acquiring five properties, contributing to an increase of 495 skilled nursing beds and 271 assisted living beds.
• Mature facilities maintained a high occupancy rate of 95.0% and saw a 0.6% increase, demonstrating stable performance in established operations.
• Average Medicaid daily rates increased by 7.7%, benefiting from state reimbursement and quality improvement programs.

Negatives

• Overall occupancy rate for skilled nursing services decreased by 1.9% to 88.9% for the nine months ended September 30, 2025, primarily due to declines in New and Ramping facilities.
• Ramping facilities experienced a significant decrease in occupancy rate by 8.2% to 86.2% and a 14.0% decrease in skilled mix by revenue.
• New facilities also saw a decrease in occupancy rate by 2.4% to 81.0% and a 1.1% decrease in skilled mix by revenue.
• Average Medicare daily rates decreased by 0.4% for the nine months ended September 30, 2025.
• Legal and other costs, primarily associated with the Audit Committee's independent investigation and ongoing government investigations, increased significantly by $66.5 million for the nine months ended September 30, 2025.
• The company has recorded $22.87 million in other liabilities for Employee Retention Tax Credits received, which may need to be returned, indicating potential future financial obligations.

Risks

• Ongoing regulatory investigations by the U.S. Department of Justice (DOJ) regarding potential False Claims Act violations related to patient referrals, Medicare billing practices (PDPM), and COVID-19 related Hospital Stay Waivers (1135 waiver).
• An SEC investigation into accounting, financial reporting, disclosure, and internal controls over financial reporting and disclosure controls.
• Securities class action and shareholder derivative lawsuits alleging a multi-year scheme to inflate revenue and profitability through improper Medicare billing and falsified documentation.
• Material weaknesses in internal control over financial reporting, specifically an ineffective control environment and inadequate controls within the revenue process, which could impair timely and accurate financial reporting.
• The company is operating under multiple forbearance agreements with its lenders due to technical events of default under its Amended and Restated Credit Facility, limiting its ability to borrow new loans and imposing restrictions on investments and acquisitions.
• The inability to predict the outcome or estimate the loss range for ongoing investigations and litigation, which could result in substantial monetary recoupments, fines, penalties, or significant legal costs.
• Dependence on reimbursement from third-party payors (Medicare, Medicaid, managed care), with changes in patient acuity, payor mix, payment methodologies, or cost-containment initiatives potentially reducing revenue and margins.
• Shortages of nurses and other skilled staff, or heightened competition for such personnel, could increase labor costs and lead to penalties.
• Concentration of facilities in certain regions (e.g., 48% of skilled nursing beds in California) increases vulnerability to local economic downturns, regulatory shifts, or natural disasters.

Future Outlook

The company expects patient and resident service revenue to continue representing the vast majority of total revenue and to increase with the successful execution of its acquisition strategy. General and administrative expenses are anticipated to increase in absolute dollar terms due to investments supporting growth and public company costs, but are expected to be leveraged over time as revenue grows. The company believes its current cash balances and cash flow from operations will be sufficient to cover operating needs for at least the next 12 months, but may seek additional capital for future growth.

Management Comments

• Our significant historical growth has been primarily driven by our expertise in acquiring underperforming long-term custodial care skilled nursing facilities and transforming them into higher acuity, high value-add short-term transitional care skilled nursing facilities.
• Our success is driven in significant part by our decentralized, local operating model, through which we empower local leaders at each facility to operate their facility autonomously and deliver excellence in clinical quality and a superior experience for our patients.
• We believe the resources and guidance offered by PACS Services is key to rapid integration of new facilities and provides our local leadership teams with an effective technology infrastructure, support tools, and regional support teams that allow local leadership to focus on operational improvements.
• Management is committed to maintaining a strong internal control environment and is taking comprehensive actions to remediate identified material weaknesses.

Industry Context

The post-acute care industry is integral to the healthcare delivery ecosystem, serving high-need patients, with growing demand outpacing the supply of skilled nursing facilities due to an aging population and increasing chronic conditions. The industry is highly fragmented, creating acquisition and consolidation opportunities for larger providers like PACS Group. Favorable reimbursement environments, particularly from Medicare and Medicaid, have seen steady increases, though the industry remains highly regulated with stringent compliance obligations.

Comparison to Industry Standards

• The company's average QM Star rating for Mature facilities is 4.3, and occupancy rate is 95%, which is strong compared to industry averages for well-established facilities.
• New facilities have an average QM Star rating of 3.3 and an occupancy rate of 81%, indicating a typical ramp-up period for newly acquired or built facilities, which often start underperforming.
• The industry is highly fragmented with approximately 15,000 facilities, where the top 10 operators represent only about 11% of the total, suggesting PACS Group's scale (320 facilities) positions it as a significant consolidator.
• Medicare and Medicaid reimbursement rates have shown a CAGR of approximately 3.6% and 1.9% respectively from 2012 to 2021, aligning with the company's reported increases in Medicaid rates.

Management Changes

Corporate Governance

Legal Proceedings

• Civil Investigative Demand (CID) from the DOJ (April 8, 2024) to Providence Administrative Consulting Services and Paradise Valley Healthcare Center, investigating False Claims Act violations related to improperly induced patient referrals through remuneration in violation of the Anti-Kickback Statute.
• CID from the DOJ (September 11, 2024) to California-based skilled nursing facilities, investigating False Claims Act violations related to submitting false claims to Medicare under the patient-driven payment model (PDPM) and practices pertaining to Minimum Data Set Assessments.
• CID from the DOJ (September 30, 2024) to Providence Group, Inc. (specifically Bishop Care Center), investigating False Claims Act violations related to submitting false claims to Medicare under the COVID-19 related Hospital Stay Waiver (1135 waiver).
• Subpoena from the DOJ (February 26, 2025) per HIPAA, investigating possible violations of 18 U.S.C. sections prohibiting fraudulent or false statements to the U.S. government, specifically concerning PACS 1135 COVID Waiver practices, Medicare Part B billing for respiratory and sensory integration therapy, insurance enrollment changes, cost waivers, and bad debt reimbursement.
• SEC Division of Enforcement investigation into the company's accounting and financial reporting and disclosure, and internal controls over financial reporting and disclosure controls.
• Securities Class Action (Manchin v. PACS Group, Inc., et al., filed November 13, 2024) alleging a multi-year scheme to inflate revenue and profitability by exploiting a COVID-era Medicare waiver, billing unnecessary Medicare Part B therapies, and falsifying licensure and staffing documentation. This action is consolidated and a lead plaintiff has been appointed.
• Shareholder Derivative Actions (IN RE PACS GROUP, INC. DERIVATIVE LITIGATION, filed February 14, 2025, and Boers v. Murray, et. al., filed August 19, 2025) against company management, based on substantially similar allegations as the Manchin Action, claiming breach of fiduciary duties, unjust enrichment, waste of corporate assets, and contribution. These actions are currently stayed pending resolution of the securities class action.
• The company is subject to an increasing number of professional liability claims, elder abuse, wrongful death, and COVID-19 related lawsuits, as well as wage and hour law violations, which are common in the skilled nursing industry and can result in significant legal expenses and settlements.

Related Party Transactions

• The company's operating subsidiaries lease and operate 269 facilities, with most leases guaranteed by the company and/or its stockholders.
• The company has equity method investments in partnerships that own the underlying real estate for 49 post-acute care facilities, some of which are leased to the company's subsidiaries. The company holds a 50.0% ownership interest in BRFS SNF Ventures V, LLC, which leases three facilities to the company, and a 25.8% ownership interest in Next Saddle Investors, LLC, which leases 37 facilities to the company.

Stakeholder Impact

• Shareholders face significant uncertainty due to ongoing regulatory investigations, class action lawsuits, and material weaknesses in internal controls, which could lead to financial penalties, reputational damage, and adverse effects on stock value.
• Employees may experience increased scrutiny and workload due to compliance remediation efforts and cooperation with investigations. Management changes, including the departure of the President and CFO, could impact morale and operational stability.
• Patients and residents could be affected by potential changes in care practices or facility operations resulting from regulatory findings or efforts to address compliance issues.
• Lenders are impacted by the company's technical events of default and the need for forbearance agreements, indicating increased risk and potentially tighter lending conditions in the future.
• Regulatory authorities are actively engaged in investigations, indicating a high level of scrutiny on the company's operations and compliance practices.

Next Steps

• Continue to implement and test remediation efforts for identified material weaknesses in internal control over financial reporting.
• Recruit a permanent Chief Compliance Officer and additional compliance, legal, and internal audit personnel.
• Engage in active discussions with Required Lenders to reach an agreement on an amendment and waiver to the Amended and Restated Credit Facility.
• Cooperate with ongoing DOJ and SEC investigations and defend against securities class action and shareholder derivative lawsuits.
• Hold the 2025 annual meeting of stockholders on December 19, 2025.
• Deliver all required documentation for Specified Joinder Subsidiaries and other entities to the Administrative Agent by November 4, 2025, and January 19, 2026, respectively.

Key Dates

Recommendation

Despite strong revenue and net income growth, the company faces severe and pervasive risks that fundamentally undermine its investment profile. The disclosure of material weaknesses in internal controls, coupled with multiple ongoing DOJ and SEC investigations into alleged False Claims Act violations and fraudulent statements, indicates significant operational and ethical failures. The existence of securities class action and shareholder derivative lawsuits further highlights potential legal and financial liabilities that are currently unquantifiable but could be material. The necessity of multiple forbearance agreements with lenders due to 'technical events of default' on its credit facility signals underlying financial instability and covenant breaches, restricting future capital access and growth. These combined factors create an extremely high-risk environment, making the stock highly speculative with substantial downside potential, regardless of current financial performance.

Keywords

Skilled Nursing Facilities, Healthcare, SEC Investigation, DOJ Investigation, False Claims Act, Internal Controls, Forbearance Agreement, Credit Facility, Revenue Growth, Net Income, Occupancy Rates, Medicare, Medicaid, Acquisitions, Management Changes, Shareholder Litigation